Amgen, Inc.

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.

A West Virginia judge rejected a preliminary injunction preventing Amgen from launching a biosimilar of Regeneron's eye drug Eylea, causing Regeneron stock to tumble. The FDA approved Amgen's Pavblu, which could launch at risk while the companies are in court. Regeneron plans to appeal, noting the decision only applies to Amgen and the standard dose of Eylea. The court battle could impact Eylea's Medicare negotiations under the Inflation Reduction Act.

Senator Bernie Sanders will lead a Senate HELP Committee hearing on Ozempic and Wegovy prices, focusing on price controls despite R&D costs and potential harm to medical innovation. The hearing aims to address the high cost of these diabetes medicines, but critics argue it overlooks the significant R&D investments required and the broader implications for future drug development.

FDA approves Sanofi's Sarclisa for use with Velcade, Bristol Myers' Revlimid, and dexamethasone in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.

Founded in 1980, Amgen is a leading biotech company in Thousand Oaks, California, focusing on human health and developing biopharmaceutical products for serious illnesses. Driven by innovation, Amgen leverages advanced technologies and scientific expertise, supported by extensive research facilities and a robust pipeline. Under CEO Robert A. Bradway, the company prioritises quality and compliance, aiming to improve patient outcomes and restore health.

The global Personalized Precision Medicine Market report offers detailed segmentation and strategic guidance, covering manufacturers, regions, product categories, and applications. Key insights include market evolution, current conditions, future projections, and analysis of key players like Agilent Technologies, Biogen, Johnson & Johnson, and Novartis. The report aids stakeholders in navigating market dynamics and capitalizing on opportunities.

DPHARM 2024 panel discussed adapting pharma operating models for efficient clinical trials, emphasizing the need to address scientific, technological, and regulatory complexities. Medicare's drug price negotiations may lower physician reimbursement. California's new 'deepfake' laws aim to regulate AI-generated content in elections. Deloitte found 50% of US women skip or delay medical care due to cost, access, or negative experiences, impacting long-term health and wealth. Parexel's poll revealed nearly 40% see the need for more agile service models in clinical trials, aligning with the rise of Functional Service Provider (FSP) models.

Extended follow-up of DeLLphi-300 trial shows tarlatamab, a bispecific T-cell engager, benefits previously treated small cell lung cancer patients with 25.0% objective response rate, 11.2 months median duration of response, and 17.5 months median overall survival. At recommended 10 mg every 2 weeks, 35.3% response rate, 14.9 months median duration, 20.3 months median survival, and 29.4% sustained disease control at ≥ 52 weeks. Intracranial activity observed in 62.5% with baseline CNS lesions ≥ 10 mm.

Amgen's recent launches, like Lumakras, have underperformed, but the $28B Horizon acquisition could boost Tepezza sales. MariTide, in phase 2 for weight loss, shows promise. Amgen's pipeline includes over 30 phase 3 programs, aiming for label expansions and biosimilars. Despite recent slow organic growth, Tezspire's success and upcoming approvals suggest future growth. Amgen offers a 2.68% forward yield, making it a reliable dividend stock.